Clinical Trial Update: Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating olverembatinib with reduced-intensity chemotherapy and venetoclax for newly diagnosed Philadelphia chromosome–positive acute lymphobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Olverembatinib (Olverembatinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED